Prader-Willi syndrome (PWS) is a rare genetic disorder affecting approximately 1 in 15,000 births. PWS is a life-threatening medical disorder caused by loss of active genetic material on chromosome 15. Nearly every system in the body is impacted by a PWS diagnosis. Among other things, PWS affects:

- hormones
- muscle strength
- appetite
- behavior
- cognition and learning
- temperature regulation
- pain tolerance
- sleep patterns

Behavior problems are also common and are worsened by an unrelenting, overriding physiological drive to eat. For someone with PWS, the feeling of fullness after eating is absent.

Currently, there is no cure for Prader-Willi syndrome. For many individuals affected by the disorder, the elimination of some of the most difficult aspects of the syndrome, such as the insatiable appetite and obesity, would represent a significant improvement in quality of life and the ability to live independently.
The Foundation for Prader-Willi Research (FPWR) is advancing research to better understand and treat Prader-Willi syndrome (PWS), with the goal of an eventual cure. We prioritize innovative research to develop new effective therapies that will positively impact the lives of those with PWS.

Our research strategy balances short-term goals of improving treatments for PWS symptoms with long-term goals aimed to develop therapies that address the root causes of the syndrome.

FPWR has developed a robust portfolio of research programs and tools to de-risk therapeutic development and address challenges at each stage of the drug development pathway, from discovery to access of new therapeutics. Our strategy aims to increase efficiency, decrease the time, and lower the costs required to bring therapeutics to market.

Research & Discovery
- Discovery programs generate critical knowledge and identify drug targets and compounds.

Pre-Clinical Development
- The PWS Cellular Network enables efficient drug screening, while the Preclinical Animal Model Network ensures that models accurately measure and predict drug efficacy and safety.

Clinical Development
- The PWS Consortium brings together stakeholders to collaboratively address the challenges of PWS clinical trials.

Post-Approval
- FPWR works with the FDA to facilitate the drug approval process for new drugs, while the Clinical Care program optimizes the use of existing drugs with the potential to treat PWS symptoms.

The PWS Registry supports all stages of the drug development pathway by providing critical information on the characteristics of PWS and expediting the enrollment and completion of clinical trials.

We believe that one day our loved ones with Prader-Willi syndrome will be able to live FULL and independent lives. With your help and support, we can make this happen!

www.FPWR.org